2 The clinical use of somatostatin analogues in the treatment of cancer
- 1 March 1990
- journal article
- review article
- Published by Elsevier in Bailliere's Clinical Endocrinology and Metabolism
- Vol. 4 (1) , 29-49
- https://doi.org/10.1016/s0950-351x(05)80314-3
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the GutAnnals of Internal Medicine, 1989
- Preoperative Treatment of Acromegaly with Long-Acting Somatostatin Analog SMS 201-995: Shrinkage of Invasive Pituitary Macroadenomas and Improved Surgical Remission Rate*Journal of Clinical Endocrinology & Metabolism, 1988
- Response of Thyrotropin-Secreting Pituitary Adenomas to a Long-Acting Somatostatin AnalogueNew England Journal of Medicine, 1987
- Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin.Journal of Clinical Investigation, 1987
- Normalization of glucose homeostasis by a long-acting somatostatin analog SMS 201-995 in a newborn with nesidioblastosisActa Endocrinologica, 1986
- Neuroendocrine Tumours of the Gut: Long-Term Therapy with the Somatostatin Analogue SMS 201-995Scandinavian Journal of Gastroenterology, 1986
- New somatostatin molecule for management of endocrine tumours.Gut, 1985
- Long term treatment of acromegaly with a long acting analogue of somatostatin.BMJ, 1985
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth HormoneScience, 1973